French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions.
Although hematopoietic stem cell transplantation (HSCT) offers curative potential for beta-thalassemia major (beta-TM), it is associated with a variable but significant incidence of graft rejection. We studied the French national experience for improvement over time and the potential benefit of antithymocyte globulin (ATG). Between December 1985 and December 2007, 108 patients with beta-TM underwent HSCT in 21 different French transplantation centers. The majority of patients received a matched sibling transplant (n = 96) and a busulfan- and cyclophosphamide-based conditioning regimen (n = 95), also with ATG in 57 cases. Ninety-five of the 108 patients survived, with a median follow-up of 12 years. Probabilities of 15-year survival and thalassemia-free survival after first HSCT were 86.8% and 69.4%, respectively. Graft failure occurred in 24 patients, 11 of whom underwent a second HSCT. The use of ATG was associated with a decrease in rejection rate from 35% to 10%. Thalassemia-free survival improved significantly with time, reaching 83% in the 54 patients undergoing HSCT after 1994 (median time of HSCT). In view of the increased risk of graft rejection after matched sibling HSCT, current French national guidelines recommend, for all children at risk for beta-TM, the systematic addition of ATG to the myeloablative conditioning regimen and special attention to optimize transfusion and chelation therapy in the pretransplantation period.
Department of Pediatric Hematology and Oncology, Service d'Hématologie Pédiatrique, Hôpital de la Timone, Marseille, France. claire.galambrun@ap-hm.fr
Claire
C
Galambrun
Corinne
C
Pondarré
Yves
Y
Bertrand
Anderson
A
Loundou
Pierre
P
Bordigoni
Pierre
P
Frange
Patrick
P
Lutz
Valérie
V
Mialou
Hervé
H
Rubie
Gérard
G
Socié
Pascale
P
Schneider
Françoise
F
Bernaudin
Catherine
C
Paillard
Gérard
G
Michel
Catherine
C
Badens
Isabelle
I
Thuret
D000293:Adolescent; D000328:Adult; D002066:Busulfan / Q000008:administration & dosage; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D008297:Male; D019653:Myeloablative Agonists / Q000008:administration & dosage; D012189:Retrospective Studies; D035781:Siblings; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D017086:beta-Thalassemia / Q000401:mortality* / Q000628:therapy*
D019653:Myeloablative Agonists; D003520:Cyclophosphamide; D002066:Busulfan